• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai , April 1

ORCHID Chemicals & Pharmaceuticals Ltd on Thursday said an anti-diabetic molecule that its US joint venture Bexel Pharmaceuticals Inc has been working on, has cleared clinical trials for toxicity and safety levels in Europe.

In a press release, the Orchid's Managing Director, Mr K. Raghavendra Rao, expressed confidence that the molecule, BLX-1002, would be licensed to manufacturers after more advanced stages of clinical trials in May.

It has generated good enquiries and the company will start negotiating with multinationals at the appropriate time.

BLX-1002 is a novel, orally active small molecule. The toxicity and safety studies constituting Phase 1(a) carried out on 42 healthy volunteers have shown that BLX-1002 is a highly safe diabetic compound. It is safe up to 1600 mg against the anticipated human dose of 20-40 mg, the release said.

The next stage of testing, Phase 1(b), will determine safety levels at repeated doses.

More Stories on : Announcements | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Reliance, Niko find gas in K-G Basin

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line